[
  {
    "ts": null,
    "headline": "Incyte price target raised to $70 from $68 at Wells Fargo",
    "summary": "Wells Fargo raised the firm’s price target on Incyte (INCY) to $70 from $68 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRa",
    "url": "https://finnhub.io/api/news?id=91890cc0869a2676fc921daefdb54bcaa9effb7b83a64d6c45ed952f4d317548",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734697239,
      "headline": "Incyte price target raised to $70 from $68 at Wells Fargo",
      "id": 132071870,
      "image": "",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Wells Fargo raised the firm’s price target on Incyte (INCY) to $70 from $68 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRa",
      "url": "https://finnhub.io/api/news?id=91890cc0869a2676fc921daefdb54bcaa9effb7b83a64d6c45ed952f4d317548"
    }
  }
]